STAT+: Eli Lilly to acquire psychedelics-focused biotech AtaiBeckley
Eli Lilly is buying the psychedelics-focused biotech AtaiBeckley for $2.8 billion upfront, a move that will expand its neuroscience pipeline.
Story detail
Read the key details here, then continue on the original publisher.
Eli Lilly is buying the psychedelics-focused biotech AtaiBeckley for $2.8 billion upfront, a move that will expand its neuroscience pipeline.
Join our channel to receive the latest headlines and breaking stories as soon as they are published.
Comments (0)
Join the conversation. Comments are rate-limited, secured, and GDPR-compliant.
No comments yet. Be the first to share your thoughts!